Evidence map›Paper›PMID 40359016›Full record

ArticleJCI insight2025

Early multiple sclerosis activity associated with TBX21+CD21loCXCR3+ B cell expansion resembling EBV-induced phenotypes.

Elliott D SoRelle, Ellora Haukenfrers, Gillian Q Horn, Vaibhav Jain, James Giarraputo, Karen Abramson, Emily Hocke, Laura A Cooney, Kristina M Harris, Scott S Zamvil and 2 more

Abstract read
In one paragraph

Article in JCI insight, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. A tonsil organoid model reveals Epstein-Barr virus-infected germinal center B cell states during primary infection.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Review
  4. Review
  5. Human CD21Journal of human immunity · 2026
    Review
  6. Article
  7. Investigations of remibrutinib in models pertinent to multiple sclerosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Elliott D SoRelleDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, USA.
Ellora HaukenfrersDuke Molecular Physiology Institute, Duke University, Durham, North Carolina, USA.
Gillian Q HornDepartment of Integrative Immunobiology, Duke University School of Medicine, Durham, North Carolina, USA.
Vaibhav JainDuke Molecular Physiology Institute, Duke University, Durham, North Carolina, USA.
James GiarraputoYale School of Medicine, New Haven, Connecticut, USA.
Karen AbramsonDuke Molecular Physiology Institute, Duke University, Durham, North Carolina, USA.
Emily HockeDuke Molecular Physiology Institute, Duke University, Durham, North Carolina, USA.
Laura A CooneyImmune Tolerance Network, Bethesda, Maryland, USA.
Kristina M HarrisImmune Tolerance Network, Bethesda, Maryland, USA.
Scott S ZamvilImmune Tolerance Network, Bethesda, Maryland, USA.
Simon G GregoryDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, USA.
Micah A LuftigDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, USA.

Funding

Immune Tolerance Network UM1 2023 SupplementUM1AI109565 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI Mark S Anderson, Jane Hoyt Buckner · 2014 to 2026
$451.6M
Targeting Apoptosis and Immune Control of Epstein-Barr Virus Infected Tonsillar B CellsR01DE025994 · NIDCR · DUKE UNIVERSITY · PI Micah Alan Luftig · 2016 to 2026
$5.0M
Basic Immunology Training ProgramT32AI052077 · NIAID · DUKE UNIVERSITY · PI KRANGEL, MICHAEL S · 2002 to 2024
$4.2M
NIAID NIH HHS T32 AI052077NIAID NIH HHS UM1 AI109565NIDCR NIH HHS R01 DE025994
6 · The paper itself

Abstract

Epstein-Barr virus (EBV) infection precedes multiple sclerosis (MS) onset and plays a poorly understood etiologic role. To investigate possible viral pathogenesis, we analyzed single-cell expression in peripheral B cells from people with early MS collected longitudinally during the Immune Tolerance Network STAyCIS Trial. Expression profiles were compared with single-cell RNA-Seq (scRNA-Seq) from in vitro EBV models, autoimmune disorders, chronic infectious diseases, and healthy controls. Analyses focused on CD19+CD20+CD21loCD11c+T-bet+ atypical B cells (ABCs). ABCs were significantly enriched in early MS PBMCs versus healthy controls by scRNA-Seq and flow cytometry, establishing ABC expansion as a clinical feature. EBV-associated ABC expression, including CXCR3, programmed cell death ligand 1 (PD-L1), and PD-L2, was enriched in early MS; however, direct EBV infection of ABCs was not detected. Early MS ABCs exhibited significantly upregulated inflammatory cytokine mRNAs (CXCL8, IL18, VEGFA). Further, de novo EBV-infected B cells secreted IL-8 and VEGF. MS activity stratification revealed rare, distinctive inflammatory ABCs significantly underrepresented in individuals with no evidence of activity long-term versus people with additional relapsing-remitting MS activity at the primary endpoint. Moreover, CXCR3+ ABCs increased after baseline diagnosis and were significantly enriched in people with disease exacerbation during the study. Thus, ABC expansion and inflammatory responses correlate to early MS activity, possibly as a bystander response to EBV.

Indexed as

B-LymphocytesEpstein-Barr Virus InfectionsHerpesvirus 4, HumanMultiple SclerosisT-Box Domain ProteinsAdultFemaleHumansMaleMiddle AgedPhenotypeReceptors, Complement 3dReceptors, CXCR3T-bet Transcription FactorCXCR3 protein, humanReceptors, Complement 3dReceptors, CXCR3T-bet Transcription FactorT-Box Domain ProteinsAutoimmune diseasesAutoimmunityImmunologyMultiple sclerosisVirology

Identifiers

PMID40359016
PMCPMC12220969

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.